Patents by Inventor Aaron K. Sato

Aaron K. Sato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180312581
    Abstract: Methods for making heteromultimeric molecules, such as bispecific antibodies, and compositions comprising these molecules are disclosed. The methods include introducing mutations in amino acids that are in contact at the interface of two polypeptides, such that the electrostatic interaction between the ion pairs is altered.
    Type: Application
    Filed: January 24, 2018
    Publication date: November 1, 2018
    Inventors: Austin L. GURNEY, Aaron K. SATO
  • Patent number: 9914771
    Abstract: Methods for making heteromultimeric molecules, such as bispecific antibodies, and compositions comprising these molecules are disclosed. The methods include introducing mutations in amino acids that are in contact at the interface of two polypeptides, such that the electrostatic interaction between the ion pairs is altered.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: March 13, 2018
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin L. Gurney, Aaron K. Sato
  • Patent number: 9845340
    Abstract: A polypeptide or multimeric polypeptide construct having the ability to bind to cMet or a complex comprising cMet and HGF, and methods for use are disclosed.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: December 19, 2017
    Assignee: Dyax Corp.
    Inventors: Daniel T. Dransfield, Aaron K. Sato, Robert Charles Ladner
  • Patent number: 9717794
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: August 1, 2017
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin L. Gurney, Aaron K. Sato
  • Patent number: 9629934
    Abstract: The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: April 25, 2017
    Assignee: Dyax Corp.
    Inventors: Aaron K. Sato, Daniel J. Sexton, Daniel T. Dransfield, Robert Charles Ladner
  • Publication number: 20160280774
    Abstract: Methods for making heteromultimeric molecules, such as bispecific antibodies, and compositions comprising these molecules are disclosed. The methods include introducing mutations in amino acids that are in contact at the interface of two polypeptides, such that the electrostatic interaction between the ion pairs is altered.
    Type: Application
    Filed: March 3, 2016
    Publication date: September 29, 2016
    Inventors: Austin L. GURNEY, Aaron K. Sato
  • Patent number: 9446155
    Abstract: The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: September 20, 2016
    Assignees: Bracco Suisse SA, Dyax Corp.
    Inventors: Aaron K. Sato, Daniel J. Sexton, Daniel T. Dransfield, Robert Charles Ladner, Christophe Arbogast, Philippe Bussat, Hong Fan, Sudha Khurana, Karen E. Linder, Edmund R. Marinelli, Palaniappa Nanjappan, Adrian D. Nunn, Radhakrishna K. Pillai, Sibylle Pochon, Kondareddiar Ramalingam, Ajay Shrivastava, Bo Song, Rolf E. Swenson, Mathew A. Von Wronski, Feng Yan
  • Publication number: 20160222108
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 22, 2015
    Publication date: August 4, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • Publication number: 20160222112
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 30, 2015
    Publication date: August 4, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • Publication number: 20160222109
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 29, 2015
    Publication date: August 4, 2016
    Applicants: Dyax Corp., Biogen Hemophilia Inc.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • Publication number: 20160222110
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 29, 2015
    Publication date: August 4, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • Publication number: 20160222111
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 30, 2015
    Publication date: August 4, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • Patent number: 9386938
    Abstract: Diagnostic compositions and methods for imaging and/or assessing collagen are described. The diagnostic compositions can include collagen binding peptides.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: July 12, 2016
    Assignee: Collagen Medical, LLC
    Inventors: Peter D. Caravan, Andrew Kolodziej, Zhaoda Zhang, Stephane Dumas, Biplab Kumar Das, Vincent Jacques, Richard Looby, Steffi K. Koerner, Wei-Chuan Sun, David R. Buckler, Aida Abujoub, Aaron K. Sato
  • Publication number: 20160194397
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 31, 2015
    Publication date: July 7, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • Patent number: 9309311
    Abstract: Methods for making heteromultimeric molecules, such as bispecific antibodies, and compositions comprising these molecules are disclosed. The methods include introducing mutations in amino acids that are in contact at the interface of two polypeptides, such that the electrostatic interaction between the ion pairs is altered.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: April 12, 2016
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron K. Sato
  • Patent number: 9260520
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: February 16, 2016
    Assignees: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James McGivney, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • Publication number: 20150374843
    Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.
    Type: Application
    Filed: April 17, 2015
    Publication date: December 31, 2015
    Inventors: Hong Fan, Karen E. Linder, Edmund R. Marinelli, Palaniappa Nanjappan, Adrian D. Nunn, Radhakrishna K. Pillai, Kondareddiar Ramalingam, Ajay Shrivastava, Bo Song, Rolf E. Swenson, Mathew A. Von Wronski, Aaron K. Sato, Sharon Michele Walker, Daniel T. Dransfield
  • Publication number: 20150337050
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
    Type: Application
    Filed: April 22, 2015
    Publication date: November 26, 2015
    Inventors: Austin L. GURNEY, Aaron K. Sato
  • Publication number: 20150218218
    Abstract: A polypeptide or multimeric polypeptide construct having the ability to bind to cMet or a complex comprising cMet and HGF, and methods for use are disclosed.
    Type: Application
    Filed: February 19, 2015
    Publication date: August 6, 2015
    Applicant: DYAX CORP.
    Inventors: DANIEL T. DRANSFIELD, AARON K. SATO, ROBERT CHARLES LADNER
  • Patent number: 9067986
    Abstract: Methods for making heteromultimeric molecules, such as bispecific antibodies, and compositions comprising these molecules are disclosed. The methods include introducing mutations in amino acids that are in contact at the interface of two polypeptides, such that the electrostatic interaction between the ion pairs is altered.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: June 30, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron K. Sato